Docket No.: 2039-0124PUS2

AMENDMENTS TO THE CLAIMS

1-10. Canceled

(Currently Amended) A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one autocrosslinked derivative of an hyaluronic acid with an average molecular weight of 150,000 to 730,000 Daltons, wherein 4.5 to 5% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule, wherein said biomaterial comprising the cross-linked derivative has a viscosity of at least 200 Pa*sec⁻¹ to 450 Pa*see⁻¹.

- 12. Canceled
- 13. Canceled
- 14. Canceled
- 15. Canceled
- 16. **(Previously Presented)** The method according to claim 11, wherein said viscosity is at least 250 Pa*sec⁻¹.
- 17. **(Previously Presented)** The method according to claim 11, 27 or 29, wherein said biomaterial further comprises a non-biodegradable synthetic polymer.

Application No. 10/812,587 Amendment dated July 9, 2008 Reply to Office Action of April 9, 2008

- 18. **(Previously Presented)** The method according to claim 17, wherein said synthetic polymer is at least one member selected from the group consisting of polypropylene, polyethylene, polyester and polytetrafluoroethylene.
- 19. **(Previously Presented)** The method according to claim 11, 27 or 29, wherein said biomaterial is in the form of a gel, a membrane, a mesh or a woven or non-woven tissue.
- 20. **(Previously Presented)** The method according to claim 11, 27 or 29, wherein said biomaterial further comprises a biologically active agent.
- 21. **(Previously Presented)** The method of claim 20 wherein said biologically active agent is selected from the group consisting of steroidal and non-steroidal antiinflammatories, fibrinolytics, hemostatics, antithrombotics, growth factors, antitumorals, antibacterials, antivirals and antifungals.
- 22. **(Previously Presented)** The method of claim 11 wherein the viscosity of said cross-linked derivative is at least 350 Pa* Sec⁻¹.
- 23. (Previously Presented) The method of claim 11 wherein the viscosity of said cross-linked derivative is at least 300 Pa* Sec⁻¹.
- 24. **(Original)** The method of claim 11 wherein said surgery is selected from the group consisting of abdominal, laparoscopic, laparotomic, intestinal, gynecologic, abdominalpelvic, peritoneal, urogenital, orthopedic, spinal/dura mater, tendon/nerve, including carpal tunnel,

Docket No.: 2039-0124PUS2

Docket No.: 2039-0124PUS2

cardiovascular, thoracic, ophtalmic, oncologic, plastic, esthetic, ENT, paranasal sinuses, and transplantation.

- 25. **(Previously Presented)** The method of claim 11, wherein the viscosity of said cross-linked derivative is at least 400 Pa* Sec⁻¹.
- 26. (**Previously Presented**) The method of claim 11, 27 or 29, wherein said auto-crosslinked derivative of an hyaluronic acid has an average molecular weight of 150,000 to 450,000 Daltons.
- (Previously Presented) A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one autocrosslinked derivative of an hyaluronic acid with an average molecular weight of 150,000 to 730,000 Daltons, wherein 4.5 to 5% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.
- 28. (**Previously Presented**) The method of claim 27, wherein said surgery is selected from the group consisting of abdominal, laparoscopic, laparotomic, intestinal, gynecologic, abdominalpelvic, peritoneal, urogenital, orthopedic, spinal/dura mater, tendon/nerve, including carpal tunnel, cardiovascular, thoracic, ophtalmic, oncologic, plastic, esthetic, ENT, paranasal sinuses, and transplantation.
- 29. (**Previously Presented**) A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one auto-

Application No. 10/812,587 Amendment dated July 9, 2008 Reply to Office Action of April 9, 2008 Docket No.: 2039-0124PUS2

crosslinked derivative of an hyaluronic acid, wherein 4.5 to 5% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.

30. (**Previously Presented**) The method according to claim 11, wherein said cross-linked derivative has a viscosity of 200 Pa*sec⁻¹ to 450 Pa*sec⁻¹.